Table 1. Clinical characteristics by baseline Ang-2 biomarker.
| Ang-2 (n=668) median biomarker level | P-value | Ang-2 low level | Ang-2 high level | P-value | |
|---|---|---|---|---|---|
|
ECOG PS | |||||
| ⩾1 | 2707.0 | 0.0036 | 168 (50%) | 191 (57%) | 0.0877 |
| 0 | 2478.0 | 166 (50%) | 143 (43%) | ||
|
Prior gastrectomy | |||||
| No | 2568.0 | 0.6129 | 240 (72%) | 241 (72%) | 1.0000 |
| Yes | 2564.0 | 94 (28%) | 93 (28%) | ||
|
Prior adjuvant/neoadjuvant chemotherapy | |||||
| No | 2607.0 | 0.0133 | 301 (90%) | 316 (95%) | 0.0405 |
| Yes | 2125.0 | 33 (10%) | 18 (5%) | ||
|
Age category, years | |||||
| 40–65 | 2515.0 | 0.1379 | |||
| <40 | 2485.5 | ||||
| ⩾65 | 2608.0 | ||||
|
Body mass index, kg m−2 | |||||
| 18.5–25 | 2393.0 | 0.0032 | 239 (72%) | 198 (59%) | 0.0011 |
| <18.5 | 2643.0 | 36 (11%) | 42 (13%) | ||
| ⩾25 | 2913.0 | 58 (17%) | 93 (28%) | ||
|
Sex | |||||
| Female | 2638.5 | 0.5450 | 102 (31%) | 114 (34%) | 0.3629 |
| Male | 2503.0 | 232 (69%) | 220 (66%) | ||
|
Liver metastasis | |||||
| No | 2374.0 | <0.0001 | 253 (76%) | 192 (57%) | <0.0001 |
| Yes | 3175.5 | 81 (24%) | 141 (42%) | ||
|
Number of metastatic sites at baseline | |||||
| ⩽1 | 2391.0 | 0.0014 | 133 (40%) | 104 (31%) | 0.0235 |
| ⩾2 | 2707.0 | 201 (60%) | 230 (69%) | ||
|
Bone metastasis at baseline | |||||
| No | 2503.0 | 0.0004 | 327 (98%) | 309 (93%) | 0.0016 |
| Yes | 3532.0 | 7 (2%) | 24 (7%) | ||
|
Type of gastric cancer | |||||
| Diffuse | 2418.5 | 0.0360 | 174 (52%) | 148 (44%) | 0.0528 |
| Intestinal | 2662.0 | 120 (36%) | 135 (40%) | ||
| Mixed | 2759.5 | 23 (7%) | 29 (9%) | ||
| Missing | 2820.0 | 17 (5%) | 22 (7%) | ||
Abbreviations: Ang-2=Angiopoietin-2; ECOG=Eastern Cooperative Oncology Group; PS=performance status. Plasma Ang-2 biomarker was dichotomised at the median to define high vs low Ang-2.